TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Panacea Biotec Ltd
PANACEABIO

Panacea Biotec Ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 42/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹372.6

Change

-2.15 (-0.57%)

Open

₹374.7

Prev. Close

₹374.75

Day High

₹378.0

Day Low

₹366.0

Volume Analysis

Traded

74,313

Delivered

31,211

Delivery %

42.0%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (-2.42%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (42/100)
  • •Low operating margin (0.3%)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹390.4 ₹384.2 ₹378.4 ₹372.2 ₹366.4 ₹360.2 ₹354.4
Fibonacci ₹384.2 ₹379.62 ₹376.78 ₹372.2 ₹367.62 ₹364.78 ₹360.2
Camarilla ₹375.9 ₹374.8 ₹373.7 ₹372.2 ₹371.5 ₹370.4 ₹369.3

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-1.34%

1 Week

-0.94%

1 Month

-5.79%

3 Months

-34.15%

6 Months

+14.54%

1 Year

-7.92%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-1.03%

Net margin -1.34% × asset turnover 0.51x × equity multiplier 1.51x

Company Overview

Sector

Healthcare

Market Cap

₹2,282 Cr

ROE

-2.42%

Book Value

₹136.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.

TopFund Analysis

Panacea Biotec Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Financial Strength (100/100), while Cash Flow (20/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-2.42%); promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

42/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

30

Valuation

50

Cash Flow

20

Corporate Governance

43

Momentum

23

Institutional Ownership

53

Business Quality

20

Risk & Volatility

44

Liquidity

28

From Screener.in

  • +Company is almost debt free.
  • −Stock is trading at 2.74 times its book value
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 0.47% over past five years.
  • −Company has a low return on equity of -3.57% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Receipt Of Demand Orders From The Office Of The Assistant Commissioner Of Income Tax, Delhi 26 Sep 26 Sep
Closure of Trading Window 26 Sep 26 Sep
Communication Sent To Physical Shareholders To Furnish PAN And KYC Details 15 Sep

Panacea Biotec asks physical shareholders to submit PAN, KYC and dematerialize shares.

Announcement under Regulation 30 (LODR)-Newspaper Publication 08 Sep

Copies of newspaper advertisement regarding Notice of 42nd AGM, Cut-off date and Remote e-Voting information, published on September 08, 2026.

Book Closure For Annual General Meeting 7 Sep 07 Sep

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 129 143 151 136 116 147 163 133 167 141 165 167 200
Expenses + 140 147 151 143 130 140 156 159 168 159 153 164 194
Operating Profit -10 -4 0 -6 -14 7 8 -27 -1 -18 12 3 6
OPM % -7.98% -2.49% -0.1% -4.43% -12.09% 4.75% 4.87% -20.28% -0.71% -12.61% 7.11% 1.54% 2.84%
Other Income + 34 6 8 14 7 7 6 36 17 9 5 5 7
Interest 1 1 1 1 1 1 1 1 1 2 2 1 1
Depreciation 9 9 9 9 9 9 9 8 8 8 8 8 8
Profit before tax 13 -8 -2 -2 -17 5 4 0 7 -19 6 -1 4
Tax % 15.73% 6.56% 33.33% -6.13% -6.86% 1.05% -1.37% 4,875.0% 39.63% -26.92% 40.06% -20.0% 38.38%
Net Profit + 11 -8 -2 -2 -16 5 4 -2 4 -14 4 -1 2
EPS in Rs 2 -1 0 0 -3 1 1 0 1 -2 1 0 0
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 687 653 544 593 457 544 625 661 460 559 559 640 673
Expenses + 643 541 505 509 591 484 548 674 558 579 584 644 670
Operating Profit 44 112 39 84 -134 60 77 -13 -98 -20 -25 -5 2
OPM % 6.0% 17.0% 7.0% 14.0% -29.0% 11.0% 12.0% -2.0% -21.0% -3.5% -4.4% -0.7% 0.3%
Other Income + 28 70 62 8 338 -21 9 1,687 154 62 55 36 26
Interest 105 127 101 101 105 174 185 181 4 4 4 6 6
Depreciation 67 73 68 57 54 43 46 44 39 37 35 33 33
Profit before tax -99 -19 -67 -66 45 -178 -146 1,449 13 1 -8 -7 -10
Tax % 3.0% 10.0% -16.0% 15.0% 17.0% 9.0% 1.0% 26.0% 363.0% 201.0% 10.0% -3.0% —
Net Profit + -108 -21 -56 -76 38 -194 -148 1,078 -34 -2 -9 -7 -9
EPS in Rs -17 -3 -9 -12 6 -32 -24 176 -5 0 -1 -1 -1
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 449 426 350 303 344 193 -235 871 837 836 829 829
Borrowings + 1,111 1,105 994 941 646 742 820 34 20 21 22 24
Other Liabilities + 364 317 440 349 379 449 587 848 407 378 433 404
Total Liabilities 1,930 1,854 1,789 1,598 1,376 1,390 1,178 1,759 1,271 1,241 1,290 1,262
Fixed Assets + 1,144 1,071 1,001 949 806 657 609 622 600 582 567 576
CWIP 155 161 30 40 23 24 34 17 42 102 128 144
Investments 15 9 7 7 5 6 0 5 13 40 3 10
Other Assets + 616 614 750 602 542 703 534 1,114 615 517 592 532
Total Assets 1,930 1,854 1,789 1,598 1,376 1,390 1,178 1,759 1,271 1,241 1,290 1,262
Equity Capital 6 6 6 6 6 6 6 6 6 6 6 6

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 37 91 131 118 105 -30 107 -108 -422 0 -27 17
Cash from Investing Activity + -37 16 -26 55 -6 -35 -48 1,283 430 10 65 -40
Cash from Financing Activity + -1 -117 -107 -164 -101 91 -47 -1,176 -18 -3 -3 -1
Net Cash Flow -1 -10 -2 9 -2 26 12 -2 -10 7 35 -25
CFO/OP 96 64 320 146 -77 -36 141 -2,235 429 -12 108 -511
Free Cash Flow 30 85 107 103 100 -21 89 -119 -424 -71 -77 -37

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 73.59% → 72.48%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 25.58% 25.46% 25.3% 25.21% 25.6% 25.96% 24.86% 25.2% 24.65% 24.31% 23.96% 22.96%
Promoters 73.59% 73.59% 73.59% 73.47% 72.87% 72.49% 72.48% 72.48% 72.48% 72.48% 72.48% 72.48%
FII 0.26% 0.26% 0.27% 0.26% 0.37% 0.38% 1.16% 0.79% 1.06% 1.36% 1.6% 2.31%
DII 0.57% 0.69% 0.84% 1.07% 1.16% 1.16% 1.49% 1.52% 1.8% 1.85% 1.96% 2.25%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Panacea Biotec Ltd (this stock) 2,282 — 2.74 -2.42%
Windlas Biotech Limited 2,274 34.2 4.01 12.2%
Fredun Pharmaceuticals L 2,305 52.6 8.2 15.6%
Indoco Remedies Ltd. 2,306 — 2.45 -9.36%
Venus Remedies Limited 2,230 19.2 3.36 16.8%
Sai Parenterals Limited 2,226 107.0 — 4.88%
Beta Drugs Limited 2,400 52.6 8.98 18.8%

Which Mutual Funds Hold Panacea Biotec Ltd?

Frequently Asked Questions about Panacea Biotec Ltd

Community Sentiment

What are other investors saying about Panacea Biotec Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.